Ildong Pharmaceutical announced on the 14th that it has participated in the ‘2021 JP Morgan Healthcare Conference’ to promote the new drug R&D pipeline.
At the conference, Ildong Pharmaceutical revealed its new drug research projects and related candidates, such as △metabolic disease treatment △liver disease treatment △eye disease treatment △solid cancer treatment.
New drug candidate’IDG-16177′ for type 2 diabetes treatment with GPR40 (G protein-binding 40 receptor) agonist mechanism and’ID11903′, a new drug project for NASH treatment with FXR (panesoid X receptor) agonist mechanism, are developed in Germany. Non-clinical research is underway through a partnership with the company Evotech.
In addition,’ID13010′, a new drug project for senile macular degeneration, which inhibits angiogenesis in the retina by acting on VEGF-A (vascular endothelial factor-A) and NRP1 (neurophilin 1 receptor), is collaborating with a global consigned development and production company. Through this, non-clinical research and clinical sample development are in progress.
‘ICP-Parkin’, which has secured 40% equity rights through direct investment and is being developed jointly, was also introduced through Cellevery, a new drug development company. iCP-Parkin is a candidate material for Parkinson’s disease, discovered by Cellibury, and is a drug designed to act directly on cranial nerve cells using the pharmacological substance in vivo transmission technology (TSDT). The company said, “Currently, iCP-Parkin is preparing for non-clinical trials such as clinical sample production through overseas consignment manufacturers, etc.,” and “We have high expectations as we are receiving proposals for partnership and technology transfer from renowned global pharmaceutical companies.” Told.
Reporter Moon Se-young email@example.com
Copyrightⓒ’Honest Knowledge for Health’ Comedy.com (http://kormedi.com) / Unauthorized reproduction-redistribution prohibited
*The article has been translated based on the content of 코메디닷컴 by kormedi.com. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!